Market Overview

Sagent Pharmaceuticals Ranked Third Fastest Growing Company in North America on Deloitte's 2012 Technology Fast 500

SCHAUMBURG, Ill., Nov. 19, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced it ranked third on Deloitte's Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America.

Sagent was recognized as achieving a 146,443% growth rate, based on the percentage fiscal year revenue growth from 2007 to 2011. The Company, which issued its initial public offering in April 2011, has a history of achieving revenue growth on a sequential basis.

"We are proud to be recognized as one of the top-three fastest growing companies by Deloitte," said Jeffrey M. Yordon, president, chief executive officer, and chairman of the board of Sagent. "This award proves that Sagent is committed to our strategic initiatives and robust growth trajectory, which will enable us to become one of the largest providers of specialty pharmaceutical products."

"We are proud to honor the 2012 Technology Fast 500™ companies, and commend them for their outstanding growth," said Eric Openshaw, vice chairman, Deloitte LLP and U.S. technology, media and telecommunications (TMT) leader. "These ground-breaking companies have outpaced their competition and are reinventing the way we do business today."

"The companies on the Fast 500 list are among those that have demonstrated remarkable innovation, creativity and business savvy," said Bill Ribaudo partner, Deloitte & Touche LLP and national TMT leader for audit and enterprise risk services (AERS). "As a result, these companies have continued to successfully forge ahead in a challenging economic environment. We applaud the leadership and employees of Sagent for this impressive accomplishment."

About Deloitte's 2012 Technology Fast 500™

Technology Fast 500, conducted by Deloitte & Touche LLP, provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies – both public and private - in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2007 to 2011.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years, and be headquartered within North America.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.

CONTACT: INVESTOR CONTACT: Jonathon Singer, Sagent (847) 908-1605 MEDIA CONTACT: Jim Polson, FTI Consulting (312) 553-6730
 

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters